Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight-photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in 6 European countries

Abstract

Background

Guidelines recommend treating actinic keratoses (AK) as they are recognized as precursors of invasive squamous cell carcinoma.

Objective

The objective of this study was to collect real-world clinical data on the use of methyl aminolevulinate daylight-photodynamic therapy (MAL DL-PDT) for the treatment of face and scalp AK in Europe.

Methods

A prospective, multicenter, non-interventional study was conducted in 6 European countries in patients receiving a single treatment of MAL DL-PDT for face and/or scalp AK. Patient-reported outcomes were assessed by patient questionnaires at baseline and at 3 months after treatment, efficacy was assessed at 3 months using a 6-point global improvement scale, and adverse events (AE) were recorded at each visit.

Results

Overall, 325 patients were enrolled from 52 investigational centers, 314 of whom attended the 3-month visit. Most patients had multiple lesions (58.4% had >10 lesions) with lesions mainly located on the scalp (60.0%) and/or forehead (54.2%). AK were predominantly grade I (39.4%) or grade II (33.2%) and 10.5% of patients had grade III lesions. The proportions of patients and physicians that were overall satisfied to very satisfied with the MAL DL-PDT treatment were 80.4% and 90.3%, respectively. The vast majority of patients (90.0%) would consider using MAL DL-PDT again if needed. Physician-assessed efficacy at 3 months was at least much improved in 83.5% of patients, with 45.9% of patients requiring no retreatment. Related AEs were reported in 15% of patients.

Conclusion

Use of MAL DL-PDT for multiple face and/or scalp AK resulted in high levels of patient and physician satisfaction in clinical practice in Europe, reflecting the good efficacy and high tolerability of this convenient procedure.

This article is protected by copyright. All rights reserved.

http://ift.tt/2jpNi10